Based on the results of the phase III ToGA (trastuzumab for Gastric Cancer) trial [3], cisplatin/fluoropyrimidine plus trastuzumab, with the latter binding to extracellular domain IV of Her-2/neu, blocking Her-2/neu signaling, and mediating ADCC, has become a standard first-line treatment for patients with Her-2/neu-positive advanced gastric cancers. The gene discussed is ERBB2; the disease is gastric cancer.